NG
NGEN
NERVGEN PHARMA CORP.
$1.92
+1.59%
$157.8M
No data for this timeframe.
Vol
Market Cap$157.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders16 funds
Inst. Value$3.1M
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases3
Recent Activity
Jun 4, 2026
short_volume
Short Volume: NGEN — 61.5% short (0.5M / 0.8M)
Short: 476,300 | Exempt: 4,545 | TRF Vol: 774,077 | Short Ratio: 61.5% | Off-exchange volume (dark p
Jun 1, 2026
SEC
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per
6-K — Impact 6/10
May 27, 2026
SEC
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th
EFFECT — Impact 4/10
May 26, 2026
SEC
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study, demo
6-K — Impact 7/10
May 22, 2026
Press
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa
Impact 6/10
May 21, 2026
Press
NervGen Pharma announced an underwritten public offering of common shares and warrants (including pre-funded warrants) t
Impact 5/10
Price Targets
$11.21
+483.6% upside
Strong Buy
Current $1.92
Low $5.03
Median $10.10
High $18.00
6 analysts
$5.03
$18.00
Analyst Ratings
1Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 ▼ -12.9% | $-0.07 — $-0.06 | 2 | |
| Next Q | $-0.07 ▼ -15.9% | $-0.07 — $-0.07 | 2 | |
| Current FY | $-0.26 ▲ +0.7% | $-0.29 — $-0.23 | 40% YoY | 2 |
| Next FY | $-0.38 ▼ -41.1% | $-0.49 — $-0.27 | -45% YoY | 2 |
Latest Reports
BEARISH
6-K
6/10
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per
Jun 1, 2026
NEUTRAL
EFFECT
4/10
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th
May 27, 2026
BEARISH
Press
6/10
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $756.5K | — |
| MARSHALL WACE, LLP | $755.4K | — |
| ROYAL BANK OF CANADA | $648.0K | — |
| BANK OF MONTREAL /CAN/ | $237.1K | — |
| CAPTRUST FINANCIAL ADVISORS | $235.1K | — |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
16 institutional holders with $3.1M total value (860,513 shares) as of 2026-Q1. Top holders: BANK, MARSHALL, ROYAL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 200,656 | $756.5K | 24.3% | — |
| 2 | MARSHALL WACE, LLP | 200,359 | $755.4K | 24.2% | — |
| 3 | ROYAL BANK OF CANADA | 171,961 | $648.0K | 20.8% | — |
| 4 | BANK OF MONTREAL /CAN/ | 62,900 | $237.1K | 7.6% | — |
| 5 | CAPTRUST FINANCIAL ADVISORS | 62,367 | $235.1K | 7.5% | — |
| 6 | COMMONWEALTH EQUITY SERVICES, LLC | 33,350 | $125.7K | 4.0% | — |
| 7 | TD Waterhouse Canada Inc. | 23,800 | $102.8K | 3.3% | — |
| 8 | ENVESTNET ASSET MANAGEMENT INC | 20,000 | $75.4K | 2.4% | — |
| 9 | Mariner, LLC | 17,875 | $67.4K | 2.2% | — |
| 10 | MORGAN STANLEY | 11,982 | $45.2K | 1.4% | — |
| 11 | CIBC WORLD MARKET INC. | 10,560 | $39.8K | 1.3% | — |
| 12 | Allworth Financial LP | 6,000 | $22.6K | 0.7% | — |
| 13 | JONES FINANCIAL COMPANIES LLLP | 1,000 | $3.7K | 0.1% | — |
| 14 | NATIONAL BANK OF CANADA /FI/ | 833 | $3.1K | 0.1% | — |
| 15 | HRT FINANCIAL LP | 21,366 | $80.00 | 0.0% | — |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 15,504 | $59.00 | 0.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 2 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.3/10.
BEARISH
6-K
6/10
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying w
Jun 1, 2026
NEUTRAL
EFFECT
4/10
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on Ma
May 27, 2026
BULLISH
6-K
7/10
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CON
May 26, 2026
BEARISH
6-K
7/10
NervGen Pharma announced a $60.0 million underwritten public offering of 24 million common shares an
May 22, 2026
BULLISH
6-K
5/10
NervGen reported Q1 2026 results with a net loss of $1.7M, improved from $3.9M a year ago due to non
May 18, 2026
BEARISH
PRESS-RELEASE
6/10
NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% m
May 18, 2026
NEUTRAL
6-K
2/10
NervGen Pharma filed a management proxy circular for its April 23, 2026 annual general meeting, seek
Apr 27, 2026
BEARISH
6/10
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with sh
May 22, 2026
BEARISH
5/10
NervGen Pharma announced an underwritten public offering of common shares and warrants (including pr
May 21, 2026
MIXED
6/10
NervGen Pharma reported full-year 2025 financial results and provided clinical updates, including co
Mar 31, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 1 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.21 mean target
+483.6% upside
Strong Buy (1.57)
$5.03 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $1.92 |
| Target Low | $5.03 |
| Target Mean | $11.21 |
| Target Median | $10.10 |
| Target High | $18.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.07 | $-0.06 | — | -12.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.07 | $-0.07 | $-0.07 | — | -15.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.26 | $-0.29 | $-0.23 | 40.2% | +0.7% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.38 | $-0.49 | $-0.27 | -45.1% | -41.1% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.066 | |
| 7d ago | $-0.066 | +0.000 |
| 30d ago | $-0.058 | -0.007 |
| 60d ago | $0.000 | -0.066 |
| 90d ago | $0.000 | -0.066 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
WHAT ARE THE BIGGEST LOSERS TODAY AND WHY
▲ 1
💬 1
⚡ 0.5
Public offering of stock: NervGen Pharmaceuticals: $ngen and what should current holders do about it?
▲ 1
💬 0
⚡ 0.5
Nervgen Pharma: $NGEN
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
short_volume
Short Volume: NGEN — 61.5% short (0.5M / 0.8M)
Short: 476,300 | Exempt: 4,545 | TRF Vol: 774,077 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 29, 2026
Clinical Trial
NVG-291 in Spinal Cord Injury Subjects
Phase Phase 2 — TERMINATED
May 29, 2026
short_volume
Short Volume: NGEN — 73.0% short (0.4M / 0.6M)
Short: 428,773 | Exempt: 0 | TRF Vol: 587,695 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: NGEN — 60.0% short (0.4M / 0.7M)
Short: 402,895 | Exempt: 1,559 | TRF Vol: 671,528 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: NGEN — 67.6% short (0.6M / 0.8M)
Short: 569,267 | Exempt: 0 | TRF Vol: 842,559 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
<p>VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 26, 2026
short_volume
Short Volume: NGEN — 73.2% short (2.1M / 2.9M)
Short: 2,114,969 | Exempt: 122,049 | TRF Vol: 2,888,570 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
May 22, 2026
offering
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
<p>VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 22, 2026
short_volume
Short Volume: NGEN — 60.2% short (4.2M / 7.0M)
Short: 4,217,437 | Exempt: 312,682 | TRF Vol: 7,005,755 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
offering
NervGen Announces Proposed Public Offering of Securities
<p>VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 18, 2026
earnings
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
<p>VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
Apr 27, 2026
other
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
<p align="left">VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a
Apr 13, 2026
other
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
<p>VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Apr 7, 2026
fda
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
<p>VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Mar 31, 2026
earnings
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
<p>VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Mar 12, 2026
delisting
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
<p>VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a